Listeria monocytogenes personalized cancer vaccines drive therapeutic immune responses to cancer derived neoantigens
B. Coder, O. Pryshchep, D. Kelkar, E. Filippova, X. Ju, D. Balli, C. Mottershead, K. Ramos, N. Thambi, Z. Cheng, B. Vander Lugt, J. Lesch, X. Liu, J. DeVoss, K. Cooke, , M. Princiotta
This study demonstrates that ADXS-NEO, a personalized Listeria monocytogenes vaccine, effectively targets tumor-specific mutations and controls tumor growth in mice by inducing neoantigen-specific T cell responses.
bioRxiv · May 11, 2020 · PreprintImmunology